Table 1.
Detailed data of the included cases
| Case no. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
|---|---|---|---|---|---|---|---|---|
| Age (years) | 45 | 40 | 69 | 52 | 39 | 46 | 65 | 60 |
| Sex | Male | Male | Male | Male | Female | Male | Male | Female |
| Diabetes mellitus | Yes | No | No | No | No | No | Yes | Yes |
| Hypertension | Yes | Yes | No | Yes | No | Yes | No | No |
| Smoking | No | No | Yes | No | No | No | No | No |
| Presentation | NSTEMI | STEMI | STEMI | STEMI | STEMI | STEMI | NSTEMI | NSTEMI |
| Complications | VT | None | AF | None | None | None | VF | Shock/AF |
| PCI site | LAD & LCX | LAD* | LAD* | LAD* | LAD* | LAD* | LAD & RCA | LAD & RCA |
| Baseline EF | 40% | 35% | 30% | 35% | 40% | 40% | 25% | 30% |
| EDV (mL) | 140 | 155 | 159 | 157 | 142 | 132 | 169 | 160 |
| Creatinine clearance (mL/min.) | 122 | 140 | 78 | 89 | 142 | 135 | 102 | 108 |
| LV thrombus size (mm) | 10x10 | 12x5 | 13x7 | 14x7 | 8x2 | 10x6 | 12x10 | 12x12 |
| HAS-BLED score | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 1 |
| Aspirin dose (mg/day) | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Clopidogrel dose (mg/day) | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 |
| Rivaroxaban dose (mg/day) | 15 | 15 | 20 | 20 | 15 | 15 | 15 | 20 |
| Follow-up EF | 50% | 55% | 45% | 50% | 55% | 55% | 35% | 50% |
| Follow-up thrombus | Absent | Absent | Absent | Absent | Absent | Absent | Present | Absent |
*
Culprit vessel.
AF - atrial fibrillation; EDV - end-diastolic volume; EF - ejection fraction; LAD - left anterior descending artery; LCX coronary intervention; RCA - right coronary artery; VF - ventricular fibrillation; VT - ventricular tachycardia